RedHill Biopharma has acquired commercialization rights to Ferring Pharmaceuticals’ Rebyota and Clenpiq for $12 million upfront, completing a broader repositioning of its gastrointestinal commercial portfolio following the previously announced divestiture of Talicia.
The two FDA-approved products generated approximately $37.5 million in combined U.S. net sales during 2025.
RedHill obtained exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq. The company will also pay Ferring tiered royalties on future net sales and potentially additional milestone payments.
The $12 million upfront payment is being funded from the $18 million upfront cash RedHill received through its Talicia divestiture, which also included up to $35 million of potential additional consideration.
RedHill says the sequence leaves it with a larger commercial GI portfolio while preserving additional liquidity.
Rebyota generated approximately $16.9 million of U.S. net sales in 2025.
The FDA-approved microbiota-based therapy is indicated for prevention of recurrence of Clostridioides difficile infection in adults following antibiotic treatment for recurrent C. difficile infection. It is not indicated to treat an active C. difficile infection.
Ferring will retain the manufacturing facilities for Rebyota and continue supplying the product during the commercialization agreement.
Clenpiq generated approximately $20.6 million of U.S. net sales during 2025 despite what RedHill characterized as minimal promotion.
The product is a ready-to-drink, low-volume bowel preparation indicated for colon cleansing before colonoscopy in adults and pediatric patients nine years and older.
RedHill sees opportunities to increase commercial activity around both products using its existing U.S. GI sales infrastructure.
Management expects the two products to make a positive cash contribution, although future commercial performance will depend on adoption, reimbursement, competition and execution.
RedHill also cited established payer coverage for both products and an existing base of approximately 600 active Rebyota accounts as potential foundations for growth.
Morningstar Law Group and Greenberg Traurig advised RedHill on the transaction.
KEY QUOTES:
“We have monetized Talicia for $18 million cash upfront, plus $35 million in potential upside, used $12 million to secure commercialization rights to two established, proprietary, FDA-approved gastrointestinal drugs, that collectively generated approximately $37.5 million in U.S. net sales in 2025, and emerged with a materially larger, fully controlled commercial business and a stronger liquidity position.”
Dror Ben-Asher, Chief Executive Officer Of RedHill Biopharma
“Together the two assets give RedHill a significantly stronger commercial growth engine in both the U.S. and other new territories.”
Rick Scruggs, Chief Commercial Officer Of RedHill Biopharma
